Cargando…
CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy
PURPOSE: (131)I therapy is regularly used following surgery as a part of thyroid cancer management. Despite an overall relatively good prognosis, recurrent or metastatic thyroid cancer is not rare. CD133-expressing cells have been shown to mark thyroid cancer stem cells that possess the characterist...
Autores principales: | Ke, Chien-Chih, Liu, Ren-Shyan, Yang, An-Hang, Liu, Ching-Sheng, Chi, Chin-Wen, Tseng, Ling-Ming, Tsai, Yi-Fan, Ho, Jennifer H., Lee, Chen-Hsen, Lee, Oscar K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510415/ https://www.ncbi.nlm.nih.gov/pubmed/23081821 http://dx.doi.org/10.1007/s00259-012-2242-5 |
Ejemplares similares
-
Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin
por: Lakshmanan, Aparna, et al.
Publicado: (2015) -
Implications of Na(+)/I(-) Symporter Transport to the Plasma Membrane for Thyroid Hormonogenesis and Radioiodide Therapy
por: Martín, Mariano, et al.
Publicado: (2018) -
Identification of CD133-Positive Radioresistant Cells in Atypical Teratoid/ Rhabdoid Tumor
por: Chiou, Shih-Hwa, et al.
Publicado: (2008) -
Evaluation of Lentiviral-Mediated Expression of Sodium Iodide Symporter in Anaplastic Thyroid Cancer and the Efficacy of In Vivo Imaging and Therapy
por: Ke, Chien-Chih, et al.
Publicado: (2011) -
CD133(+ )adult human retinal cells remain undifferentiated in Leukaemia Inhibitory Factor (LIF)
por: Carter, Debra A, et al.
Publicado: (2009)